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longation of AV and VA conduction time were determined. The 1:1 AVand
VA conduction cycle lengths before injection of adenosine were 340 ± 50
and 326 ± 75 msec, respectively. Adenosine induced dose-dependent pro-
longation of AV nodal conduction time and caused typical Wenckebach AV
block in all 16 patients with ECso and Emax values of 1.4 ± 0.8 mg and 54
± 2%, respectively. Adenosine also induced dose-dependent prolongation
of VA conduction time and VA block, however, with significantly (P <: 0.051
higher ECso and shorter Emax , i.e., 6.1 ± 1 mg and 20 ± 2%, respectively.
The mean dose of adenosine to induce AV block is significantly lower than
that to induce VA block (3.3 ± 1.6vs. 7.7 ± 3.3 mg, P <: 005). Notably, adeno-
sine induced Wenckebach VA block in 10 of 16 patients and Mobitz type II
block in 6 of 16 patients. In conclusion, adenosine is more potent in slowing
AV than VA conduction, suggesting that the electrical wavefront entering the
N zone of AV node is less affected by adenosine during VA than during AV
conduction. In addition, retrograde fast pathway may at least in part involve
conduction through the N zone of AV node.
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1798-31 A Comparison of Amlodarone versus Flecalnide
Using a Quinidine Standard in the Treatment of
Resistant Chronic Atrial Fibrillation
Dawn G. Zarembski, Paul E. Nolan, Manon K. Slack, Anthony C. Caruso. University
ofArizona. Tucson, AZ
Chronic atrial fibrillation (AFI IS a ommon arrhythmia with significant mor-
bidity and mortality. The antiarrhythmic effects of amiodarone (AMI and fle-
cainide (FLEe) in patients with resistant chronic AF have been studied sep-
arately in several small clinical trials. This study compared AM to FLEC in
maintaining normal sinus rhythm (NSR) in patients (pts)with resistant chronic
AF. To facilitate the comparison, quinidine (OUIN) was used as the reference
standard.
Studies using AM or FLEC in the treatment of chronic AF refractory to
either Class I AF drugs or sotalol were identified. The results of 6 trials of
AM (200-400 mg/day; 315 pts) and 2 trials of FLEC (200-300 mg/day; 163
ptsl were aggregated using meta-analysis in NSR at 3 and 12 mos for AM
and FLEC were compared relative to corresponding results for OUIN, which
were acquired from a meta-analysis of OUIN used as first-line therapy for AF.
Duration of chronic AF ranged from 2 wks to 25 yrs. After 3 and 12 mos
of treatment with AM, 217 of 299 (72.6%) and 64 of 107 (59.8%1 pts, re-
spectively, remained in NSR. These percentages were significantly greater
(p <: 0.00011 when compared to OUIN at these time points (70% and 50%,
respectively). After 3 and 12 mos of treatment with FLEC, the percentage of
pts remaining in NSR were significantly lower (p <: 0.00011 than OUIN: 79
of 163 (48.5%) and 56 of 163 (34%) pts, respectively. The aggregated per-
centages of pts requiring withdrawal of AM and FLEC were 9.5% and 8.6%,
respectively. Mortality and proarrhythmia could not be assessed.
Conclusion: This analysis suggests that low-dose AM is more efficacious
and equally well-tolerated when compared to FLEC in the management of
chronic, drug-resistant AF.
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1798-41 Predictors of the Efficacy of Sotalol, a Class III
Antiarrhythmic Agent, In the Treatment of Atrial
Arrhythmias
Robert A. Schweikert, Harvey L. Leo, Mina K. Chung. Cleveland Clinic Founda~'on,
Cleveland, OH
Sotalol. a class III antiarrhythmic drug (MD) approved for use in ventricu-
lar arrhythmias, is being used with increasing frequency for supraventricular
arrhythmias (SVA). To determine the efficacy of sotalol in the treatment of
SVA and the predictors of sotalol failure or intolerance, 114 pts in whom 50-
talol was begun for SVA were reviewed. All pts had atrial fibrillation (109)
andlor atrial flutter (32) (AF: paroxysmal in 76, chronic in 351, except for 3
who had SVT. Mean duration after diagnosis of SVA was 5.2 ± 8.2 yrs. The
mean number of priorfailed MDs was 1.96 ± 1.27 (range 0-6). Electrical car-
dioversion was achieved in 38/41 pts; 18 pts pharmacologically converted.
Sotalol was stopped prior to discharge in 16 pts (Inefficacy in 8, side effects
in 4, prolonged OT in 2, and no longer indicated in 2). Prior to discharge,
proarrhythmia occurred in 1 pt and bradycardia in 15 pts. 26 pts had prior
pacemakers, and 11 pts required pacemakers for sotalo!. Mean discharge
dose was 229 ± 78 mglday and mean discharge OTc was 462 ± 59 ms.
Predictors for discontinuation of sotalol prior to discharge included degree
of left atrial enlargement (LAE, p = 0.03) and OTc on sotalol (p = 0.0631.
Of 88 pts discharged on sotalol in sinus rhythm, 52 developed recurrent SVA
(mean flu 7.8 mos). After dose changes, 3 more pts became recurrence free.
Of 36 recurrence-free pts, 12 had sotalol discontinued (side effects in 7, no
longer indicated in 5). 2 pts discharged on sotalol developed proarrhythmia,
and 2 pts died (1 noncardiac and 1 CVA). Overall, 27/114 pts (23.6%1 begun
on sotalol remained recurrence free and on the drug. Of 10 pts who began
sotalol as first line antiarrhythmic therapy, 2 stopped sotalol in the hospital,
2 after hospital discharge, and 2 recurred after discharge (overall 40% recur-
rence free on sotalol). Univariate predictors of recurrent SVA on sotalol for
pts discharged in NSR included younger age (60 ± 13 vs 68 ± 9 yrs, p =
0.001), longer duration since diagnosis of SVA (7.7 ± 11 vs 2.8 ± 4.0 yrs, p
~ 0.009), prior CABG (p = 0.01), number of failed MDs (2.4 ± 1.3 vs 1.4 ±
1.1, P = 0.00031. and shorter baseline OTc (441 ± 46 vs 465 ± 59 ms, p =
0.0491 and discharge ORS (109 ± 32 vs 128 ± 41 ms, p = 0.025). Changes
in HR or OTc were not significant predictors of sotalol success. Significant
multivariate predictors of SVA recurrence adjusted for the follow-up period
included number of failed MDs (p = 0.00241. discharge ORS (p = 0.0038)
and age (p = 0.03). In summary, sotalol showed moderate (24%) efficacy
in pts previously refractory to MDs and comparable efficacy as a first-line
agent to that reported with other AADs. Changes in OT interval or HR could
not be used to predict long term efficacy.
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Risk of Initiating Antiarrhythmic Drug Therapy for
Atrial Fibrillation
William H. Maisel, Thomas H. Lee, Elliott M. Antman, Sharon C. Reimold, Peter
L. Friedman, William G. Stevenson Brigham and Women's Hospital, Boston, MA
The side effects of antiarrhythmic drugs for atrial fibrillation (AF) are well rec-
ognized, but the incidence and time course of early events that justify ob-
servation in-hospital, are not well defined. Adverse cardiac events requiring
intervention were determined for 169 consecutive hospitalized patients un-
dergoing 253 trials of Class I or III antiarrhythmic drugs for AF. Patient charac-
teristics were: age 64 (25-86) yrs, male 60%, structural heart disease 89%
and prior myocardial infarction 18%. Adverse cardiac events occurred in 37
(15%) drug trials in 33 patients an average of 2.6 ± 1.1 days after initiation
of therapy. The majority (65%) occurred within 3 days. The actuarial risk of
cardiac events is shown in the Figure below. Of the 37 events, there were
26 (70%) bradyarrhythmias and 2 (5%) ventricular arrhythmias. Age, gender,
and absence of structural heart disease were similar between patients with
or without events. A previous history of myocardial infarction was associated
with an increased risk of cardiac event (RR 2.1, P = 0.06). Conclusion. Brad-
yarrhythmias are the most common adverse cardiac event during initiation
of drug therapy for AF. A strategy of hospitalization for electrocardiographic
monitoring for 24-48 hours-after initiation of antiarrhythmic therapy is likely
to miss some adverse cardiac events.
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1798-61 Acute Effects of Zatebradine on Cardiac Conduction
and Repolarlzatlon In Anesthetized Dogs
Luyi Sen, Guanggen Cui, Yoshiheda Sakaguchi, Bramah N, Singh. UClA, School of
Medicine & VAMCILA, Los Angeles, CA
Zatebradine, a potent bradycardic agent, is believed to act selectively at the
sinoatrial node. However, the selectivity of such an action relative to various
electrophysiologic classes of action is not well defined. To characterize tie
electrophysiologic properties of zatebradine, the corrected sinus node recov-
ery time (SNRT/sinus cycle length), sinoatrial conduction time (SACT), con-
duction intervals, effective refractory period in atrium (AERP) and monopha-
sic action potential duration (APDso) in ventricle were measured before (Ctrl)
and after administration of incremental doses of zatebradine (Zat, 0.1-1.5
mglkg) in 15 anesthetized dogs. The effects of zatebradine on various elec-
trophysiologic parameters could be observed immediately after a single i.v.
bolus and reached steady-state at 15 min.
Results (Mean ± S.D.):
